Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
samatasvir
- Development stage
- Phase 2
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Samatasvir is an orally administered, potent, and selective small molecule inhibitor of the hepatitis C virus (HCV) nonstructural protein 5A (NS5A), a key component in HCV replication. It was originally developed by Idenix Pharmaceuticals and later continued by Merck & Co. after acquiring Idenix. Samatasvir demonstrated pan-genotypic activity against HCV genotypes 1 through 5 with low picomolar EC50 values in vitro, indicating high potency. The drug reached Phase II clinical trials for the treatment of chronic hepatitis C infection but its development was ultimately discontinued. Samatasvir showed additive effects when combined with other antiviral agents and retained full activity in the presence of HIV and HBV antivirals[1][3][5][7].
- Other names
- samatasvir
02
Targets
NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))
Beyond the preview
Go deeper on samatasvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on samatasvir.